17 Aug 04
DailyUpdates 18th August, 2004: Researchers from at Arizona State University have demonstrated that beta amyloid light chain proteolytic antibody fragments can cleave beta-amyloid, altering the aggregation and neutralizing the cytotoxic effects of this peptide.
17 Aug 04
In recent years a greater effort has been made by international healthcare organizations and governments to tackle diseases that have their heaviest impact in the developing world. Many of these diseases have been called â€˜neglected diseasesâ€™ as few new drugs have been launched to tackle them during the last 20 years.
Dr Faiz Kermani
13 Aug 04
Rigel's new intranasal inhibitor R112 could offer a useful alternative therapy for patients suffering from allergic rhinitis, as Datamonitor's Shaun Falkingbridge explains. Bolstered by supportive recent trial results, Rigel can now go on to seek partner firms to realize full commercialization of the drug...
12 Aug 04
The trade in discounted prescription drugs between Canada and the US has elicited considerable controversy on both sides of the border. Yet recent figures show that sales of drugs via Canadian pharmacies have not been as great as some had predicted. However, as Datamonitor's David Deon explains, pharmaceutical companies could go further by driving the expansion of online prescribing in the US...
11 Aug 04
The p38-MAPK pathway has long been targeted by the pharmaceutical industry in an attempt to identify new anti-inflammatory agents. The development of p38-MAPK inhibitors has however been impeded by adverse effects. Boston University researchers have now demonstrated that the lipoxin A4 (LXA4) mimic, ATLa inhibits the p38-MAPK cascade explaining in part its anti-inflammatory efficacy and offering a new approach to this promising pharmaceutical target. Although ATLa has a poor pharmacokinetic p
10 Aug 04
After a period of exceptional performance due to a steady flow of investment in the sector, the biotechnology industry in France was hard hit by the global economic depression of 2002. The government must support the French Biotechnology sector to allow it to assert its position at an international level and to enable consolidation of new start-up companies.
03 Aug 04
Bacterial skin diseases like gangrene can now expect an onslaught of new specialist medications. However, skin infections make up a relatively small proportion of the $20.4 billion annual global antibacterial market, which, says Datamonitor's Amber Gibson, raises questions about why such conditions are the current focus of so much antibacterial product development...
29 Jul 04
Although generics have an important role to play in healthcare there remains a high demand for innovative medicines. Consequently, a number of generics companies have become interested in extending their R&D programmes to make their products appear more than simple copies of their branded competitors.
Dr Faiz Kermani
26 Jul 04
By 2012, the anti-obesity drugs market will be worth an estimated $2.5 billion globally, compared to $526 million today. However, new drugs will not be the answer to the growing obesity problem. Datamonitor's Jasjeet Mohain argues that increasing education and awareness of the importance of good diet and exercise will remain crucial to combating obesity...
19 Jul 04
New clinical research presented at the 15th International AIDS Conference (IAC) shows that Fuzeon is proving to be remarkably effective in the first long-term trial of its benefits.
14 Jul 04
What exactly is a Curriculum Vitae? Is it a List of your Skills and Experience? Is it a Mini Biography? Is it a chance to get someone to fully appreciate your Skills and Achievements?
Truth be known, Itâ€™s none of these.
13 Jul 04
Acute pain resulting from conditions such as headache, muscle spasms, dental problems or following surgery, affects 90 million Americans every year. A recent study has demonstrated the analgesic activity of corticotropin-releasing-hormone (CRH) and has shown that this activity is probably due to activity within the central nervous system.
09 Jul 04
Analysts have recently predicted that the market for airway inflammatory diseases will increase by 35% to over $18 billion by 2011. A recent target evaluation report produced for the drug development sector concluded that the TH2-derived cytokines IL-4, and more so IL-13 represent promising targets. Both cytokines activate IL-4Ralpha to produce multiple functional changes observed in asthma patients. A recent report published in the Journal of Immunology elucidates the divergent mechanisms th
09 Jul 04
Recently published data from the GENOA study has demonstrated that dyslipidemia is highly prevalent in hypertensive adults and that this condition is insufficiently treated in more than half of the cases. As Datamonitor's Laurent Chanroux explains, the results lend further support to cross risk-factor, single pill combination therapies such as Pfizer's Caduet...
05 Jul 04
SureScripts, in partnership with the Massachusetts Medical Society, is launching an educational network providing physicians with information from the early adopters of ePrescribing technology. Datamonitor's Kimberly O'Malley argues that educational forums like this allow members to more efficiently evaluate and subsequently adopt electronic prescribing as a solution for their practices...
30 Jun 04
Structuring the Deal--
Contract Development and Negotiations for Improved Results
29 Jun 04
This edition of "Emerging Drug Discovery Targets" features new approaches to improving intestinal uptake of poorly absorbed therapeutics; a dual 5-LO inhibitor/H1 receptor antagonist for the treatment of asthma; Sitaxentan as an effective treatment of pulmonary arterial hypertension; Kv1.3 potassium channel blockade as an approach to insulin resistance; Drug delivery technology predicted to allow safer and more effective use of steroids in the treatment of rheumatoid arthritis; VEGF receptor tyr
25 Jun 04
Rheumatoid arthritis is one of the more common autoimmune diseases. LeadDiscoveryâ€™s recent state of the art evaluation of rheumatoid arthritis therapeutics evaluates advances in our understanding of the etiology of the disease. One field of research extensively analyzed in this report is angiogenesis. Inhibitors of receptor tyrosine kinase with specific activity against the VEGFRs have been developed in an attempt to prevent angiogenesis. One such molecule is PTK787/ZK222584, synthesized and dev
23 Jun 04
An estimated 5 million individuals suffer from rheumatoid arthritis. Corticosteroids are the most dramatically effective short-term anti-inflammatory drugs; however, clinical benefit for rheumatoid arthritis often diminishes with time. Because of their long-term systemic side effects, corticosteroids are usually given only after a careful and prolonged trial of less hazardous drugs. Liposomes are artificial vesicles efficiently phagocytosed by macrophages and recent advances such as the developm
23 Jun 04
â€˜To change Career, or to change Company?â€™ Although these seven words are easy to utter (and utter you will, over and over again), they are actually very deceptive as really what you are asking is, â€˜Which direction should my life now take?â€™
22 Jun 04
The R&D activity surrounding novel oral treatments of diabetes is considerable and one particular target that has recently received attention is the Kv1.3 potassium channel. Blocking this channel has been thought to be of value in the treatment of multiple sclerosis and more recently for preventing weight gain. Now researchers from Yale have demonstrated that Kv1.3 channel blockers may also increase insulin sensitivity in genetically obese and diabetic mice
21 Jun 04
Pulmonary arterial hypertension (PAH) represents an unmet market. Initial breakthroughs in treatment focussed on the rare form of this condition, idiopathic pulmonary arterial hypertension. Recently however a key advance in the treatment of PAH was made with the launch of Actelion's twice-daily Tracleer (bosentan) as the first orally active treatment of both idiopathic and secondary PAH. Tracleer is the first generation of a class of drugs known as endothelin receptor antagonists and blocks two
20 Jun 04
Numerous inflammatory mediators have been implicated in the etiology of asthma. Blocking specific inflammatory mediators has frequently yielded unimpressive clinical results and instead the simultaneous targeting or more than one mediator may be of greater use. In the current edition of LeadDiscovery's TherapeuticAdvances work by researchers at UCB who have developed a dual 5-LO inhibitor/H1 receptor antagonist is highlighted
17 Jun 04
PABORD is the first exhibition and conference dedicated to Outsourcing in Research and Development for the Pharmaceutical and Biotechnology industries.
17 Jun 04
As we all know, interviews come in three forms: The good, the bad, and sometimesâ€¦ The downright ugly! This is an article about the latter; ugly interviews, from â€˜unconventionalâ€™ interviewers, who wouldnâ€™t know the words â€˜Professional, Un-biased and Independentâ€™ even if they came up and bit them!
16 Jun 04
Pharma NewsBytes selects out some of the most interesting press releases to have appeared on LeadDiscoveryâ€™s DailyUpdates tracking service over the past few weeks. This edition includes an update on selected releases from the American Society of Clinical Oncology and the American Diabetes Association as well as important news concerning the antipsychotic, Abilify (Aripiprazole) and novel HIV treatments
16 Jun 04
Researchers have developed a series of assays to identify improved DDP-IV inhibitors for the treatment of diabetes and possibly cancer. The technology described here can also be applied to improving the oral absorption of poorly absorbed drugs in general